logo
Fossil footprints describe a day in the life of a 50 million-year-old shorebird

Fossil footprints describe a day in the life of a 50 million-year-old shorebird

CNN25-04-2025

About 50 million years ago, a small bird waded along a lakeshore in what today is central Oregon. A worm wriggled at its feet. The bird appeared to probe the silty earth with its beak, once, twice, three times, looking for food. On the fourth try, the bird may have found something. Or perhaps it missed again and moved on.
This glimpse into prehistory is possible thanks to two tiny fossil footprints and the dogged work of an undergraduate intern at John Day Fossil Beds National Monument with a particular interest in ancient tracks, known as trace fossils.
'Trace fossils definitely do tell stories,' said Conner Bennett, lead author of a study describing the find and three others that was published in February in the journal Palaeontologia Electronica. 'We don't have the body of this bird. It's more just like we're left with its actions, its behaviors. It's like trying to study ghosts.'
Trace fossils can fill in gaps in the fossil record, said Dr. Anthony Martin, professor of practice in the department of environmental sciences at Emory University in Atlanta. 'This paper has tracks that are definitely from a bird of some sort, and then tracks that are definitely from a lizard,' said Martin, who researches modern and fossil traces and was not involved in the research. 'So those are showing that those animals actually were there, even though there's not a single bone or feather or any other bodily evidence of those two types of animals being there.'
The science of trace fossils isn't as 'sexy' as studying bones, teeth and other physical remains, Bennett said. Fossilized tracks don't get as much attention. That's part of the reason he got the chance to undertake this research in the first place. Bennett, now a graduate student in the department of Earth, environmental and planetary sciences at the University of Tennessee, Knoxville, applied for a summer internship at John Day in 2022. The national monument holds a rich paleontological record from the Eocene Epoch — part of the age of mammals — which lasted from about 56 million to 34 million years ago.
Bennett combed through the park's online catalog of finds and came across several animal track impressions that had been found decades ago but never studied. He'd previously worked with 3D modeling software to describe dinosaur tracks and endeavored to give the unidentified animal tracks the same treatment.
The analysis could help researchers form a better understanding of the prehistoric ecosystems of Oregon. Bennett said he hopes his findings will inspire other researchers to look for trace clues they may have previously overlooked. 'I'm sure it's going to happen soon where people are like, 'Oh, it's really interesting to learn about fossil tracks. Let's pull this stuff out of our archives and start looking at it.'
While interning at John Day, Bennett took hundreds of overlapping photos of four sets of fossilized tracks, each only centimeters in size. He fed the pictures into the modeling software, which created 3D representations that could be blown up, zoomed in on and scrutinized in greater detail than the fossils.
In one, there were tracks that reminded him of a small shorebird, such as a plover. There aren't bird fossils in John Day, he explained — the bones are fragile and hollow and don't hold up well. But it would make sense that there would be such birds near the lake that once covered the area where the tracks were excavated.
There were also small, round indentations near the tracks. At first, Bennett and study coauthor Dr. Nicholas A. Famoso — the head paleontologist and museum curator at John Day — thought they could be caused by raindrops, which can leave impressions in the fine grains of shale and clay the tracks were found in. But there are usually many raindrop impressions, and here there were only a few, and only near the footprints. The researchers wondered whether the bird had made them with its beak. Bennett went online and quickly turned up a video of modern plovers pecking into the ground, hunting for food. The connection seemed clear to the research team.
Not only did the trace fossil confirm the previously unproved existence of birds in the area tens of millions of years ago, but it also could paint a picture of how the birds foraged in the shallow water — much the way they do today. And to complete the picture, the fossil contained evidence of what the bird was feeding on or trying to feed on: the squiggly trail of a worm on the move. 'We can track a feeding behavior over 50 million years. That's pretty cool,' Bennett said.
Dr. Danielle Fraser, head of paleobiology at the Canadian Museum of Nature in Ottawa, who was not involved in this study, expressed a similar sentiment. 'This is a really cool example of a behavior that would otherwise not be apparent,' she said.
Martin suggested an alternative interpretation: that the divots could have been made by water droplets falling off the bird's body as it came out of the water. 'I've seen that a lot on the Georgia coast,' he noted.
A separate specimen showed three footprints made up of five thin, splayed digits and clawlike impressions, suggesting some small lizard once darted along the lakeshore. There were even marks showing where the lizard dragged its feet. The researchers found this exciting because there are few examples of tracks from small lizards in North America in this period, and no body fossils have been unearthed at John Day.
'Too few paleontologists are trained in the recognition and interpretation of trace fossils and so a lot of this information is overlooked,' said study coauthor Dr. Daniel I. Hembree, professor and director of undergraduate geology studies in the University of Tennessee department where Bennett is studying.
The traces are the only evidence of small lizards' existence at John Day during the Eocene.
'The fossils of the bird and lizard are the first evidence of those groups of animals from that period of time in our fossil record,' Famoso said. They 'help to paint a more complete picture of what life was like' during the Eocene.
Bennett also analyzed two other trace fossils — from mammals from a more recent time period. One showed prints of a three-toed ungulate, possibly a rhinoceros or ancient tapir. The other: the 29 million-year-old tracks from what the researchers believe to be some sort of saber-toothed cat.
The absence of claw marks suggested that the animal's claws were retractable, like those of modern cats. And the gait appears similar, too, Martin said. The way the rear paw print only partially overlaps the front means the animal may have been walking at a normal pace. 'This is the kind of understep gait that I see in my cats at home,' he said. 'I get kind of excited when I see something that looks so familiar.'
Famoso noted that both sets of prints were found in an ash layer, which means the animals walked across an ash-laden landscape after a volcanic eruption.
'Sometimes fossils are stored in collections until new technologies or methods are developed that can better study them,' he added. 'These fossils were collected and added to collections between 1979 and 1987, but it took until 2022 for us to get a good study out to describe the specimens.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

A long-running experiment finds a tiny particle is still acting weird
A long-running experiment finds a tiny particle is still acting weird

Yahoo

time3 days ago

  • Yahoo

A long-running experiment finds a tiny particle is still acting weird

NEW YORK (AP) — Final results from a long-running U.S.-based experiment announced Tuesday show a tiny particle continues to act strangely -- but that's still good news for the laws of physics as we know them. 'This experiment is a huge feat in precision,' said Tova Holmes, an experimental physicist at the University of Tennessee, Knoxville who is not part of the collaboration. The mysterious particles called muons are considered heavier cousins to electrons. They wobble like a top when inside a magnetic field, and scientists are studying that motion to see if it lines up with the foundational rulebook of physics called the Standard Model. Experiments in the 1960s and 1970s seemed to indicate all was well. But tests at Brookhaven National Laboratory in the late 1990s and early 2000s produced something unexpected: the muons weren't behaving like they should. Decades later, an international collaboration of scientists decided to rerun the experiments with an even higher degree of precision. The team raced muons around a magnetic, ring-shaped track — the same one used in Brookhaven's experiment — and studied their signature wiggle at the Fermi National Accelerator Laboratory near Chicago. The first two sets of results — unveiled in 2021 and 2023 — seemed to confirm the muons' weird behavior, prompting theoretical physicists to try to reconcile the new measurements with the Standard Model. Now, the group has completed the experiment and released a measurement of the muon's wobble that agrees with what they found before, using more than double the amount of data compared to 2023. They submitted their results to the journal Physical Review Letters. That said, it's not yet closing time for our most basic understanding of what's holding the universe together. While the muons raced around their track, other scientists found a way to more closely reconcile their behavior with the Standard Model with the help of supercomputers. There's still more work to be done as researchers continue to put their heads together and future experiments take a stab at measuring the muon wobble — including one at the Japan Proton Accelerator Research Complex that's expected to start near the end of the decade. Scientists also are still analyzing the final muon data to see if they can glean information about other mysterious entities like dark matter. 'This measurement will remain a benchmark ... for many years to come,' said Marco Incagli with the National Institute for Nuclear Physics in Italy. By wrangling muons, scientists are striving to answer fundamental questions that have long puzzled humanity, said Peter Winter with Argonne National Laboratory. 'Aren't we all curious to understand how the universe works?' said Winter. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

At-home health tests are here. But they aren't always the best option
At-home health tests are here. But they aren't always the best option

Yahoo

time4 days ago

  • Yahoo

At-home health tests are here. But they aren't always the best option

The doctor is in — the mailbox, that is. You can now do self-administered tests for everything from thyroid function to HIV in the privacy of your own home — and that list continues to grow, as the Food and Drug Administration recently approved the first at-home cervical cancer test. While the tests can make it easier for people to access health care and can be helpful for those who have extreme anxiety about sensitive or invasive medical exams, experts warn that most of the tests cannot replace an actual in-person visit. Here's what doctors say you can test for at home, and when you should make the trek to your physician's office. What kinds of at-home tests are available? There are two kinds at 'at-home tests.' In one type, the patient collects the sample and sends it off to a lab; the new cervical cancer test is like this. The other gives an instant result — think COVID-19 and pregnancy tests. What are the benefits of at-home tests? HIV home-testing kits can improve rates of diagnosing sexually transmitted infections in rural communities and help people who are nervous about going to the doctor to seek a sensitive test, said Dr. Joseph Cherabie, an infectious diseases specialist in St. Louis. 'You really want to get people to care as quickly as possible, but some people could be very anxious about that results as well," Cherabie said. "And they have very negative reactions.' Labs are required to report a positive HIV test, instead of putting the onus on the patient who took the test, Cherabie said, and and, often, the patient is matched up with HIV support services. 'If you are part of a sexual and gender minority community, going to a doctor's office can be full of a lot of historical trauma, and you may prefer to just do testing at home without anyone judging you or asking you invasive questions about your sex life,' Cherabie said. The new cervical cancer test — which tests for strains of human papillomavirus, or HPV — involves a testing swab that's like a tampon, said Dr. Susan Modesitt, a gynecologic oncologist at Emory University in Atlanta. It is not, Modesitt said, a replacement for a Pap smear, the exam in which a metal speculum is inserted in the vagina to scrape cervix cells. A doctor's visit also involves a pelvic exam, a chance to talk about abnormal bleeding — a sign of endometrial cancer — and other symptoms and issues, like menopause or STIs. 'There are so many other reasons to see your doctor and get an exam outside of a cervical cancer screening,' she said. I live in a rural area — can I take an at-home test? Some at-home tests can replace a trip to the doctor's office. That's especially true in rural areas, where it can be difficult to get a colonoscopy. 'The colonoscopy requires a pre-op, and you have to drive maybe 70 miles for it,' said Dr. Steven Furr, board chair of the American Academy of Family Physicians who practices in rural Alabama. 'You get anesthesia. It's actually almost like a surgical procedure in many ways. "So, for a lot of people, that's pretty arduous. That's where an at-home test can come in handy.' But, Furr said, if your test reveals issues, you need to go to your doctor. Plus, patients should always discuss test results with their physician instead of interpreting them on their own, he said. Who shouldn't do at-home tests? If you have symptoms of what you're testing for, go to the doctor. At-home colon cancer tests aren't the right option for people with a history of colon cancer or high-risk conditions, such as inflammatory bowel disease, said Dr. Zachariah Foda, a gastroenterologist at Johns Hopkins. He added that they're also not recommended for people who are having GI symptoms. While there are tests for many things — running anywhere from $15 to $400, depending on what is being evaluated — Furr said it's essential to make sure that your test is FDA-approved so you can better trust the results. 'Anytime we get people involved in their own health care and help them understand what's going on, I think that's a good thing and it gives us a chance to talk,' he said. 'Any kind of screening is better than no screening.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Devna Bose, The Associated Press Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Yahoo

time27-05-2025

  • Yahoo

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies in the neoadjuvant setting that are associated with improved pathologic response in patients with head and neck cancer. Lead investigator and collaborator, Conor Steuer, MD from Winship Cancer Center at Emory University, will present results at the 2025 Annual Meeting of Clinical Oncology (ASCO) in Chicago on June 1, 2025. ASCO Conference Information: Date: Sunday, June 1, 2025 Presentation title: Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer. Abstract 103. Time: 9:45-11:15 AM CST/10:45 AM – 12:15 PM EST. Session Title: Clinical Science Symposium – Turning 'Cold' Tumors 'Hot' Previously reported data from our collaboration with Emory University suggest a crucial role of pepinemab treatment in melanoma patients to facilitate immune cell interactions within highly organized and robust centers of immunity, called tertiary lymphoid structures, or TLS. By blocking the SEMA4D inhibitory signal to Dendritic Cells (DC), pepinemab allows productive, coordinated interactions between SEMA4D+ T cells, key effector cells capable of eradicating tumors, and DC, regulatory cells that promote immune cell interactions within TLS so as to amplify mature T cell responses. New data presented at ASCO will characterize the mechanisms of neoadjuvant treatment with pepinemab in patients with resectable head and neck cancer (HNSCC). Standard of care for these patients often involves toxic chemotherapy and/or radiotherapy, in addition to surgery, which can significantly impact their quality of life. Peri-operative treatment with immunotherapy has recently reported promising and potentially practice-changing results. Certain HNSCC with hot beds of immune cells organized into TLS have been shown to correlate with clinical benefit and positive response to immune checkpoint therapy. However, many HNSCC are considered immunologically 'cold' tumors, due to exclusion of immune cells from tumor and/or high levels of immune suppressor cells, making them resistant to immune checkpoint therapy. Pepinemab has potential to be a major advance for HNSCC patients with cold and resistant disease, with capacity of a well-tolerated and effective treatment that can induce formation and harness the power of TLS to optimize the clinical benefit of immunotherapy. Our data demonstrate that the addition of pepinemab to neoadjuvant immune checkpoint treatments did not compound toxicities, yet it enhanced TLS maturity that correlated with improved pathologic response. Collectively, these results highlight the potential of pepinemab to turn immunologically cold tumors, such as HPV-negative head and neck cancer, into hot immune centers by inducing robust and mature TLS. About PepinemabPepinemab is a humanized IgG4 monoclonal antibody designed to block SEMA4D, which can otherwise bind to plexin-B1 receptors to trigger collapse of the actin cytoskeleton and lead to loss of homeostatic functions of dendritic cells in immune tissue and of astrocytes and other glial cells in the brain. Pepinemab appears to be well-tolerated with a favorable safety profile in multiple clinical trials in different cancer and neurological indications. About Vaccinex Inc. Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents infiltration and activation of immune cells in tumors and triggers damaging inflammation in neurodegenerative diseases. In oncology, pepinemab is also being evaluated in combination with KEYTRUDA® in the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC) and in combination with BAVENCIO® in a Phase 1b/2 study in patients with metastatic pancreatic adenocarcinoma (PDAC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma. We believe pepinemab has also given promising results as a monotherapy in the Phase 1b/2 SIGNAL-AD study in Alzheimer's Disease, and the Company has previously published promising Phase 2 data suggesting a slowing of cognitive decline in Huntington's disease. Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc. Kenilworth, NJ, USA. Additional information about the study is available at: KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. BAVENCIO®/avelumab is provided by Merck KGaA, Darmstadt, Germany, previously as part of an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer. Forward Looking StatementsTo the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. ('Vaccinex,' 'we,' 'us,' or 'our'), they are forward-looking statements reflecting management's current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of the KEYNOTE-B84 and SIGNAL-AD clinical trials; the use and potential benefits of pepinemab in R/M HNSCC, lung cancer, metastatic pancreatic adenocarcinoma (PDAC) and other indications; the potential for benefits as compared to single agent KEYTRUDA® or BAVENCIO®; expectations with respect to the collaboration of Merck,; and other statements identified by words such as 'anticipate,' 'believe,' 'plans,' 'schedule,' 'being,' 'will,' 'appears,' 'expect,' 'ongoing,' 'potential,' 'promising,' 'suggest', and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical studies and clinical trials, that interim and preliminary data may not be predictive of final results and does not ensure success in later clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, the Company assumes no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled 'Risk Factors' in our previous reports filed with the Securities and Exchange Commission and the other risks and uncertainties described in the Company's 2024 year-end Form 10-K filed with the SEC. CONTACT: Investor Contact Elizabeth Evans, PhD Chief Operating Officer Senior Vice President, Vaccinex, Inc. (585) 271-2700 eevans@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store